neoANT-HILL

neoANT-HILL identifies putative neoantigens from Next Generation Sequencing (NGS) data to support cancer immunogenomics and personalized immunotherapy research.

Key Features:

• Integrated Pipeline: Integrates multiple immunogenomic analysis pipelines for neoantigen detection from NGS data to reduce false-positive rates.
• Automation: Automates the identification of potential neoantigens from sequencing-derived inputs.
• Multi-sample Analysis: Supports analysis of single and multiple samples simultaneously for cohort or individual studies.
• Input Data Types: Accepts RNA sequencing reads and somatic DNA mutations as input and considers RNA-Seq data for comprehensive neoantigen identification.
• Binding Predictors: Provides several binding predictors to assess neoantigen-TCR interactions.
• Tumor Microenvironment Profiling: Enables quantification of tumor-infiltrating immune cells to inform neoantigen relevance.
• Performance Validation: Demonstrated high sensitivity and specificity on datasets including the TCGA melanoma dataset, identifying neoantigens such as RAC1:P29S and SERPINB3:E250K.

Scientific Applications:

• Cancer Research: Facilitates discovery and characterization of tumor-derived neoantigens for immunogenomic studies in cancer.
• Personalized Medicine: Supports development of targeted immunotherapies by identifying patient-specific neoantigens for personalized treatment strategies.

Methodology:

Integrates multiple immunogenomic analysis pipelines; accepts RNA sequencing reads and somatic DNA mutation inputs; employs multiple binding predictors to assess neoantigen-TCR interactions; and performs quantification of tumor-infiltrating immune cells.